Adagio Follow Up Study

• Research type

  Research Study

• Full title

  An Open-Label, Multi-Centre, Follow-Up Study designed to evaluate the long term effects of rasagiline in Parkinson's Disease in subjects who participated in the Adagio study

• IRAS ID

  23001

• Contact name

  David Burn

• Sponsor organisation

  Teva Pharma GmbH

• Eudract number

  2009-011541-24

• Clinicaltrials.gov Identifier

  N.A

• Research summary

  This is a follow up study to the Phase III Adagio study TVP-1012 500. The result of the 72 week Adagio study provides evidence that treating patients in the early stage of their Parkinson's disease with rasagiline 1 mg slows down clinical progression of the disease. This follow up study will collect data over a period of 2 years to look at the long term changes in the disease pattern of patients who participated in the Adagio study. Only patients who participated in the Adagio study will be eligible and invited to take part in this follow up study.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  09/H0405/34

• Date of REC Opinion

  9 Oct 2009

• REC opinion

  Further Information Favourable Opinion